^
    Apply
    Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) (NCT03767348)
    Phase 2
    Replimune Inc.
    Recruiting
    Last update posted :
    01/24/2025
    Initiation :
    09/20/2017
    Primary completion :
    12/01/2025
    Completion :
    12/01/2028
    BRAF • MSI
    |
    MSI-H/dMMR • BRAF mutation
    |
    Opdivo (nivolumab) • vusolimogene oderparepvec (RP1)
    "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer (NCT06067061)
    Phase 1/2
    Institut Curie
    Recruiting
    Last update posted :
    05/30/2024
    Initiation :
    04/05/2024
    Primary completion :
    04/05/2026
    Completion :
    04/05/2031
    HER-2
    |
    HER-2 overexpression
    |
    Tecentriq (atezolizumab) • vusolimogene oderparepvec (RP1)